---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-023274"
form_type: "8-K"
ticker: "STRO"
cik: "0001382101"
company_name: "SUTRO BIOPHARMA, INC."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:12:46.877898+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sutro BioPharma Q3 revenue $25.1M, cash $287.3M; STRO-002 data at ASH, Phase 2 design by year end

## Summary
- Revenue $25.1M (up from $8.5M YoY); total operating expenses $46.4M.
- Cash, equivalents and marketable securities $287.3M as of Sep 30, 2022; projected runway into first half 2024.
- STRO-002 oral presentation at ASH 2022 for pediatric AML; Phase 1 ovarian data and Phase 2 design expected by end 2022.
- Vaxcyte positive Phase 1/2 data for VAX-24; Sutro to receive 4% royalties on worldwide net sales.
- Astellas collaboration with $90M upfront received; Merck $10M milestone triggered.

## SEC filing metadata
- accession: 0000950170-22-023274
- form_type: 8-K
- ticker: STRO
- cik: 0001382101
- company_name: SUTRO BIOPHARMA, INC.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382101/000095017022023274/0000950170-22-023274-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382101/000095017022023274/stro-20221108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-023274
- JSON: https://secwatch.observer/filing/0000950170-22-023274.json
- Plain text: https://secwatch.observer/filing/0000950170-22-023274.txt

## Key facts
- Earnings Releases
  SUTRO BIOPHARMA, INC. reported financial results for quarter ended September 30, 2022.
  - Period: quarter ended September 30, 2022
  - Result: reported results
  source text: On November 8, 2022, Sutro Biopharma, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1382101/000095017022023274/0000950170-22-023274-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.